Previous Issue
Volume 13, April
 
 

Vaccines, Volume 13, Issue 5 (May 2025) – 3 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Section
Select all
Export citation of selected articles as:
1278 KiB  
Review
Developing a Vaccine Against Human Cytomegalovirus: Identifying and Targeting HCMV’s Immunological Achilles’ Heel
by Anastasia Lankina, Marta Raposo, Alexander Hargreaves, Claire Atkinson, Paul Griffiths and Matthew B. Reeves
Vaccines 2025, 13(5), 435; https://doi.org/10.3390/vaccines13050435 - 22 Apr 2025
Abstract
Human cytomegalovirus (HCMV) is a critical pathogen in immunocompromised populations, such as organ transplant recipients as well as congenitally infected neonates with immature immune systems. Despite decades of research and the growing financial burden associated with the management of HCMV, there is no [...] Read more.
Human cytomegalovirus (HCMV) is a critical pathogen in immunocompromised populations, such as organ transplant recipients as well as congenitally infected neonates with immature immune systems. Despite decades of research and the growing financial burden associated with the management of HCMV, there is no licensed vaccine to date. In this review, we aim to outline the complexity of HCMV and the antigens it presents and the journey and challenges of developing an effective HCMV vaccine, as well as further highlight the recent analyses of the most successful vaccine candidate so far—gB/MF59. Full article
(This article belongs to the Section Vaccines against Infectious Diseases)
Show Figures

Figure 1

133 KiB  
Correction
Correction: Dors et al. Effect of Vaccination Against E. coli, C. perfringens Type A/C on Piglet Productive and Clinical Parameters Under Field Conditions. Vaccines 2024, 12, 1185
by Arkadiusz Dors, Robert Panek, Wojciech Łużyński, Krzysztof Janeczko, Agata Augustyniak, Hanna Turlewicz-Podbielska, Ewelina Czyżewska-Dors and Małgorzata Pomorska-Mól
Vaccines 2025, 13(5), 434; https://doi.org/10.3390/vaccines13050434 - 22 Apr 2025
Abstract
The authors would like to make the following corrections to this published paper [...] Full article
819 KiB  
Review
HPV Vaccine Delivery Strategies to Reach Out-of-School Girls in Low- and Middle-Income Countries: A Narrative Review
by Erica N. Rosser, Megan D. Wysong, Joseph G. Rosen, Rupali J. Limaye and Soim Park
Vaccines 2025, 13(5), 433; https://doi.org/10.3390/vaccines13050433 - 22 Apr 2025
Abstract
Background/Objectives: Low- and middle-income countries (LMICs) have the highest global burden of cervical cancer deaths. Human papillomavirus (HPV) vaccination is a key strategy for cervical cancer elimination, and in LMICs, global recommendations to vaccinate girls aged 9–14 years against HPV are generally implemented [...] Read more.
Background/Objectives: Low- and middle-income countries (LMICs) have the highest global burden of cervical cancer deaths. Human papillomavirus (HPV) vaccination is a key strategy for cervical cancer elimination, and in LMICs, global recommendations to vaccinate girls aged 9–14 years against HPV are generally implemented through school-based immunization platforms. Unfortunately, this strategy risks missing out-of-school (OOS) girls (i.e., girls not enrolled in formal schools). This narrative review maps the literature and synthesizes existing evidence on service delivery strategies for reaching OOS girls with HPV vaccination in LMICs. Methods: Using relevant databases, we conducted a narrative review of published, peer-reviewed literature to map and synthesize the existing evidence on effective service delivery strategies for reaching OOS girls with HPV vaccination in LMICs. Results: The 21 articles identified presented findings on strategies to reach OOS girls, with the most frequently cited strategies being facility-based and community outreach approaches. Authors also described community-based strategies used to identify and enumerate OOS girls, including peer tracing, church outreach initiatives, as well as partnerships with local groups (e.g., civil service organizations) and individuals (e.g., healthcare workers, teachers). The articles discussed barriers at the individual (e.g., lack of parental consent), facility/program delivery (e.g., lack of transportation for vaccines), and community (e.g., distance from homes to vaccination services) levels to HPV vaccine delivery, as well as solutions at the facility/program delivery (e.g., pilot programs) and community (e.g., multi-level partnerships) levels. Conclusions: Additional research is needed to evaluate implementation strategies targeting OOS girls with HPV vaccination. A better understanding of these strategies can provide valuable insights for HPV vaccine policymakers, healthcare providers, and program implementers. Full article
(This article belongs to the Special Issue Prevention of Human Papillomavirus (HPV) and Vaccination)
Show Figures

Figure 1

Previous Issue
Back to TopTop